Armodafinil and similar wakefulness-promoting agents create a dangerous illusion: they mask sleep debt without resolving it. Short-term cognitive benefits (focus, alertness) come at the cost of cumulative neurological damage — memory loss, cognitive decline, and impaired recovery. The mechanism is deceptive because the user feels more functional while their brain deteriorates. Real sleep is the only sustainable cognitive performance strategy; pharmacological alertness is borrowed time with compound interest. ## Source - **Author**: Brian Roemmele - **Source**: [[I’m shocked—absolutely floored—that some smart folks out there, like tech...]] - **Date**: 2026-02-22 ## Cross-References - [[Stress as Energy Deficit]] - [[Subtraction Based Quality of Life Optimization]] - [[Population vs Individual Health Evidence]] - [[Brain Lymphatic Drainage System]] — the mechanism this note gestures at: sleep is when the brain's waste-clearance pathways do their work, which masked sleep debt skips - [[Armodafinil Promotes Wakefulness, Not Verified Cognitive Enhancement]] — grounds the drug claim in FDA/DrugBank pharmacology; flags the neurological-damage claim above as under-verified - [[Sleep Debt Is Modeled as Adenosine Pressure, Not a Ledger]] — the physiological mechanism this note's "masked without resolving" claim depends on